GlassScriptPhysician profile
Joel H Datloff
NPI 1477581817
$6,316.82
in general payments reported to CMS, 2019-2025
26 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $211 · 2021: $663 · 2022: $739 · 2023: $1,531 · 2024: $1,344 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,696 · Education: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.36 |
| Education | $386.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,880.49 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,003.06 | 2019-2025 | Skyrizi, Humira, Botox |
| Ucb, INC. | $588.01 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $427.05 | 2019-2025 | |
| Amgen INC. | $309.66 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $304.50 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $270.39 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $260.29 | 2019-2024 | Dupixent |
| Pfizer INC. | $240.57 | 2019-2023 | |
| Galderma Laboratories, L.P. | $222.19 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $129.09 | 2019-2024 | Arazlo, Jublia |
| Lilly USA, LLC | $128.27 | 2019-2021 | |
| Incyte Corporation | $103.60 | 2022-2023 | Opzelura |
| Leo Pharma INC. | $93.62 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $67.70 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $57.39 | 2025 | Zoryve |
| Fresenius Kabi USA, LLC | $38.02 | 2023 | Idacio |
| Almirall LLC | $34.46 | 2019-2022 | |
| Blueprint Medicines Corporation | $24.46 | 2023 | |
| Vyne Pharmaceuticals INC. | $24.25 | 2021 | |
| Allergan, INC. | $23.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.93 | 2024 | Simlandi |
| Dermavant Sciences, INC. | $18.23 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.23 | 2023 | Spevigo |
| Organon LLC | $16.22 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Datloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.